Medicare Price ‘Negotiation’ Process Could Enable National Value Framework – CMS’ Blum

Centers for Medicare and Medicaid Services chief operating officer Jonathan Blum discusses implementation of an unprecedented new price setting program and how it might impact value-based pricing more broadly in a recent interview with Health Affairs.

Blum 'Optimistic' Negotiation WIll Promote Consensus On Value • Source: Shutterstock

The Medicare drug price negotiation program established by the Inflation Reduction Act could help move the US toward a framework for determining drug value and how much to pay for it, according to Centers for Medicare and Medicaid Services principal deputy administrator and chief operating officer Jonathan Blum.

“I think … what the benefit of the drug negotiation process will be is a greater consensus for both payers...

More from Pricing Debate

More from Market Access